期刊文献+

丹参酮ⅡA、苦参碱、川芎嗪对PC12细胞抗肿瘤活性的研究 被引量:2

Study on anticancer activities of tanshinone ⅡA,matrine and ligustrazine on adrenal pheochromocytoma PC12 cells
下载PDF
导出
摘要 目的观察丹参酮ⅡA、苦参碱、川芎嗪对肾上腺嗜铬细胞瘤PC12细胞的抑制作用,并比较3种药物的抗肿瘤活性。方法依据文献分别对丹参酮ⅡA、苦参碱、川芎嗪设定给药浓度,配制9种不同的浓度,对PC12细胞处理24 h,采用MTT测定吸光度值,再根据Origin软件计算细胞的IC50值,比较3种药物对PC12细胞的抗肿瘤作用。结果通过丹参酮ⅡA、苦参碱与川芎嗪对PC12细胞抗肿瘤作用比较,发现丹参酮ⅡA组肿瘤细胞生长明显受抑制。各组IC50值分别为23.21 nmol/mL、11.36μmol/mL、20.32μmol/mL。丹参酮ⅡA、苦参碱与川芎嗪比较,肿瘤细胞生长明显受抑制,差异有统计学意义(P<0.05)。结论与苦参碱及川芎嗪对比,丹参酮ⅡA在低浓度时对肿瘤细胞就有抑制作用,具有显著的抗肿瘤活性。 Objective To observe the inhibitory action of tanshinone Ⅱ A,matrine and ligustrazine on adrenal pheochromocytoma PC12 (a tumor in the sympathetic nervous system),and make a comparison among the three medicaments in terms of their anti-tumor and MDR effect.Methods Different settings for tanshinone Ⅱ A,matrine and ligu strazine were designed according to the document,and PC12 cells were treated with 9 solutions of different concentration.MTT was used to determine the value of optical density,and IC50 value of bacterial was measured by the Origin Soft.The anti-tumor effects of tanshinone Ⅱ A,matrine and ligustrazine were compared.Results Tanshinone Ⅱ A solution had obvious inhibition on PC12 cells,IC50 values of bacterial in tanshinone Ⅱ A group,matrine group and ligustrazine group were 23.21 nmol/mL,11.36 μmol/mL,20.32 μmol/mL,respectively.The tumor cells with the treatment of tanshinone Ⅱ A solution was inhibited greatly,and there were significant differences among the tanshinone Ⅱ A group and those of the other groups (P < 0.05).Conclusion Compared with matrine and ligustrazine,tanshinone ⅡA has inhibitory effect on tumor cells at a low concentration with significant antineoplastic activity.
出处 《实用药物与临床》 CAS 2014年第12期1523-1527,共5页 Practical Pharmacy and Clinical Remedies
基金 辽宁省科学技术计划项目(2012225020)
关键词 丹参酮ⅡA 苦参碱 川芎嗪 PC12 Tanshinone Ⅱ A Matrine Ligustrazine PC 12
  • 相关文献

参考文献5

二级参考文献58

共引文献71

同被引文献73

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部